HC-5404 improves response to VEGFR-TKIs and ICIs in preclinical models
May 10, 2023
Researchers from Hibercell Inc. presented preclinical data for the eukaryotic translation initiation factor 2-α kinase 3 (PERK) inhibitor HC-5404, currently in phase I development for the treatment of solid tumors (NCT04834778).
